Akumina Named A Strong Performer in 2020 Intranet Platforms Evaluation by Leading Independent Research Firm
16.6.2020 18:47:00 EEST | Business Wire | Press release
Akumina, the leading global Employee Experience Platform (EXP) software provider and one of INC Magazine’s Top 200 fastest growing companies in North America, announced today that they’ve been named a Strong Performer by Forrester Research, Inc. in The Forrester Wave™: Intranet Platforms, Q2 2020 report.
Akumina received the highest scores possible in seven criteria, including Personalization, Integration & Interoperability, and Design Tools.
Akumina’s inclusion in this evaluation is important especially to large enterprises working to improve employee experience, as it shows the strength and innovation of the organization’s technology. Many large enterprise customers like Banner Health, ING, and GlaxoSmithKline have already successfully partnered with Akumina.
“The Forrester Wave report is a well-respected resource for global organizations looking to partner with a software vendor ranked favorably in product quality, overall strategy, industry expertise and proven customer success,” says Akumina President and Co-Founder, David Maffei. “We feel being named a Strong Performer in the Forrester Wave reinforces our belief in the power of our platform and our strategy. It’s humbling and exciting to earn such a high honor from a respected independent third party like Forrester.”
Customer perspective is also considered an important part of the evaluation, which states, “Reference customers attest to the power of Akumina’s design tools, ease of content creation/editing, and ability to personalize communication.”
Akumina is laser focused on transforming the employee experience for medium and large enterprises around the globe with north of 4.5 million daily active users and customers using the platform in 80 countries and in over 60 different languages.
“Our intranet has become a unified, personalized platform connecting our employees to tools, information and each other. It empowers employees to take action, find solutions and share knowledge and experiences,” says Keith Kratochvil, Enterprise Architect at long-time Akumina customer the Principal Financial Group.
Akumina has also received recognition from organizations like ClearBox Consulting, The Tech Tribune, and CIO Review and has partnered with industry leaders such as Avanade, the leading digital innovator in the Microsoft ecosystem.
“Avanade is extremely excited with Akumina’s inclusion and placement in the 2020 Forrester Wave Report for Intranet Platforms. We took a strategic position in Akumina to help our clients to drive adoption and effective use of Digital Workplace tools at enterprise scale and we’ve seen our enterprise clients achieve strong results pivoting to a Digital-Hub-on-Akumina approach to reduce day-to-day friction in their organizations,” said Florin Rotar, Executive, Global Modern Workplace Lead at Avanade & Accenture Microsoft Business Group.
To learn more about Akumina, or to download a copy of the Forrester Wave™ Report on Intranet Platforms, please visit www.akumina.com.
About Akumina
Akumina is the employee experience platform that empowers global enterprises to quickly create personalized digital experiences that help every employee in every role work smarter, not harder. By offering a customizable, brandable and multilingual platform that seamlessly integrates with leading enterprise cloud applications, Akumina delivers a contextual, collaborative, and engaging workplace experience to every user on any device. Akumina’s customers include ING, Principal Financial Group, Whole Foods Market, GlaxoSmithKline, Vodafone, the Boston Red Sox and the Department of Defense. To learn more visit www.akumina.com or follow us on LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005822/en/
Contact information
Michael Scott
VP of Marketing
Michael.Scott@akumina.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
